Table 1 Patient and treatment characteristics
5-FU+MMC ( n =47) | Capecitabine+MMC ( n =58) | ||||
---|---|---|---|---|---|
Characteristic | No. | % | No. | % | P -value |
Age (years), median (range) | 53.5 (36.8–83.8) | 59.3 (41.3–86.4) | 0.277 | ||
Gender | |||||
Male | 23 | 49 | 22 | 38 | 0.322 |
Female | 24 | 51 | 36 | 62 | |
T-classification | |||||
T1 | 1 | 2 | 0 | 0 | 0.837 |
T2 | 20 | 43 | 29 | 50 | |
T3 | 18 | 38 | 19 | 33 | |
T4 | 8 | 17 | 10 | 17 | |
N-classification | |||||
N0 | 22 | 47 | 18 | 31 | 0.103 |
N1 | 13 | 28 | 19 | 33 | |
N2 | 9 | 19 | 9 | 16 | |
N3 | 3 | 6 | 10 | 17 | |
Nx | 0 | 0 | 2 | 3 | |
UICC stage | |||||
Stage 0 | 0 | 0 | 0 | 0 | 0.221 |
Stage I | 0 | 0 | 0 | 0 | |
Stage II | 17 | 36 | 14 | 24 | |
Stage III | 30 | 64 | 42 | 72 | |
Stage IV | 0 | 0 | 0 | 0 | |
Not known | 0 | 0 | 2 | 3 | |
Primary tumour site | |||||
Anal canal | 40 | 85 | 50 | 86 | 0.957 |
Anal margin | 5 | 11 | 5 | 9 | |
Both | 2 | 4 | 3 | 5 | |
HIV status | |||||
Negative | 12 | 26 | 27 | 47 | 0.078 |
Positive | 7 | 15 | 4 | 7 | |
Unknown | 28 | 60 | 27 | 47 | |
SCC tumour marker | |||||
Normal (<2.0 μg l−1) | 24 | 51 | 36 | 62 | 0.223 |
Elevated (⩾2.0 μg l−1) | 22 | 47 | 19 | 33 | |
Unknown | 1 | 2 | 3 | 5 | |
DPYD *2A genotype | |||||
Wild type | 7 | 15 | 56 | 97 | 1.000 |
Heterozygous | 0 | 0 | 1 | 2 | |
Unknown | 40 | 85 | 1 | 2 | |
Radiation technique | |||||
CF-RT | 24 | 51 | 0 | 0 | — |
IMRT | 23 | 49 | 58 | 100 | |
Radiation dose | |||||
Surdosage given? | 5-FU+CF-RT | 5-FU+IMRT | Capecitabine+IMRT | ||
Yes | 24 (100%) | 19 (83%) | 32 (55%) | — | |
No | 0 (0%) | 4 (17%) | 26 (45%) | ||
Total radiation dose to primary tumour, median (range) | 64.8 (64.8–66.6) | 64.8 (59.4–68.4) | 64.8 (59.4–70.2) | — | |
Total radiation dose to LNs, median (range) | 64.8 (45.0–66.6) | 54.9 (49.5–58.5) | 54.9 (49.5–60.3) | — |